Mga Batayang Estadistika
| CIK | 1418133 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biostar Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 24, 2018 |
Biostar Pharmaceuticals Announces Receipt of Additional Delisting Determination Letter from Nasdaq Exhibit 99.1 Biostar Pharmaceuticals Announces Receipt of Additional Delisting Determination Letter from Nasdaq XIANYANG, China, August 23, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (the “Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on August 16, 2018, it received a notification letter from Nasdaq Listing |
|
| August 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2018 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Emp |
|
| July 25, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2018 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Emplo |
|
| July 25, 2018 |
Biostar Pharmaceuticals Received Nasdaq Delisting Notification Exhibit 99.1 Biostar Pharmaceuticals Received Nasdaq Delisting Notification XIANYANG, China, July 25, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on July 19, 2018 it received a notification letter from Nasdaq Listing Qualifications (“Nasdaq”) advising the C |
|
| July 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2018 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employ |
|
| July 2, 2018 |
BSPM / Biostar Pharmaceuticals, Inc. / Liu Waiping - SC 13D Activist Investment SC 13D 1 sc13dliu062818.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Biostar Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 090678301 (CUSIP Number) Waiping Liu Flat G, 14/F Begonia Mansion 8 Tai Koo Wan Road +852-9160-2311 (Name, Address and Telephone |
|
| July 2, 2018 |
Share Purchase Agreement, dated June 4, 2018, by and between Waiping Liu and Ronghua Wang. Exhibit 99.1 SHARE PURCHASE AGREEMENT 股份购买协议 This Share Purchase Agreement (the "Agreement") is made as of the 4th day of June, 2018 by and between Ronghua Wang, with the People's Republic of China (the "PRC") Passport No. (the "Seller") and Waiping Liu, with PRC Hong Kong Special Administrative Region Passport No. (the "Purchaser"). 本股份购买协议（"本协议"）于2018年6月4日由中华人民共和国（"中国"）护照号为E85615992的王荣华("卖方")和中国 |
|
| May 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2018 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employ |
|
| May 30, 2018 |
Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice Exhibit 99.1 Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, May 30, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on May 23, 2018 it received a notification letter from Nasdaq Listing Qualifications (“Nasdaq”) advisin |
|
| May 16, 2018 |
BSPM / Biostar Pharmaceuticals, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): o Form 10-K ☐ Form 20-F ☐ Form 11-K x Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| April 23, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2018 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Empl |
|
| April 23, 2018 |
Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice Exhibit 99.1 Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, April 23, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on received a notification letter from Nasdaq Listing Qualifications (“Nasdaq”) advising the Company |
|
| April 2, 2018 |
BSPM / Biostar Pharmaceuticals, Inc. NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): ☒Form 10-K ☐Form 20-F ☐Form 11-K ☐Form 10-Q ☐Form N-SAR ☐Form N-CSR For Period Ended: December 31, 2017 ☐Transition Report on Form 10-K ☐Transition Report on Form 20-F ☐Transition Report on Form 11-K ☐Transition Report on Form 10-Q ☐Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| February 2, 2018 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 biostar8k020218.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2018 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Juris |
|
| February 2, 2018 |
Mazars letter dated February 2, 2018. Exhibit 16.1 Our ref.: PS/SC/B397/AUD3/pp February 2, 2018 Securities and Exchange Commission 100F Street NE Washington DC 20549 United States Dear Sirs, We have read Item 4.0l (a) of Biostar Pharmaceuticals, Inc's Form 8-K, which discusses the resignation of Mazars CPA Limited as its independent registered public accounting firm, and we agree with the statements made therein. Yours faithfully, Ma |
|
| February 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2018 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Em |
|
| December 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2017 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. E |
|
| December 18, 2017 |
8-K 1 biostar8k121317.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2017 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Juri |
|
| December 18, 2017 |
Exhibit 17.1 BY EMAIL ONLY Flat A, 20/F Yun Kai Building 466-472 Nathan Road Kowloon Hong Kong [email protected] 12 December 2017 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang City, Shaanxi Province People's Republic of China 712046 [email protected] Attn: The board of directors Dear Sir/Madam Re: Resignation as Independent Director I, LEUNG King Fai hereby tender my resigna |
|
| December 4, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 biostar8k120417.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2017 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Juri |
|
| December 4, 2017 |
Biostar Regains Compliance with NASDAQ Continued Listing Requirement EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biostar Regains Compliance with NASDAQ Continued Listing Requirement XIANYANG, China, December 4, 2017 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) (“Biostar” or “the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced that on November 30, 2017, it received a letter from the NA |
|
| November 20, 2017 |
BSPM / Biostar Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: September 30, 2017 Or ☐ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOS |
|
| November 15, 2017 |
BSPM / Biostar Pharmaceuticals, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: September 30, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| November 15, 2017 |
BSPM / Biostar Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: June 30, 2017 Or ☐ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR P |
|
| October 13, 2017 |
BSPM / Biostar Pharmaceuticals, Inc. ESP Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People's Republic of China 712046 October 13, 2017 VIA SEC EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Ibolya Ignat, Senior Staff Accountant Frank Wyman, Senior Staff Accountant Re: Biostar Pharmaceuticals, Inc. Form 10-K for |
|
| October 2, 2017 |
BSPM / Biostar Pharmaceuticals, Inc. ESP Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People's Republic of China 712046 October 2, 2017 VIA SEC EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Ibolya Ignat, Senior Staff Accountant Frank Wyman, Senior Staff Accountant Re: Biostar Pharmaceuticals, Inc. Form 10-K for |
|
| August 28, 2017 |
Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, August 28, 2017 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on August 22, 2017 it received a notification letter from Nasdaq Listin |
|
| August 28, 2017 |
8-K 1 biostar8k082517.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2017 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisd |
|
| August 15, 2017 |
Biostar Pharmaceuticals NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: June 30, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| June 12, 2017 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2017 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employ |
|
| May 19, 2017 |
Biostar Pharmaceuticals 10-Q (Quarterly Report) 10-Q 1 biostar10q033117.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: March 31, 2017 Or ☐ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commissio |
|
| May 15, 2017 |
Biostar Pharmaceuticals NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: March 31, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| April 21, 2017 |
Biostar Pharmaceuticals DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 13, 2017 |
Biostar Pharmaceuticals 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2016 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR PHARM |
|
| April 13, 2017 |
Biostar Pharmaceuticals, Inc. List of subsidiaries EX-21 2 ex21.htm EX-21 Exhibit 21 Biostar Pharmaceuticals, Inc. List of subsidiaries As of December 31, 2016 Name Place of incorporation Shaanxi Biostar Biotech Ltd People’s Republic of China Shaanxi Aoxing Pharmaceutical Co. Ltd. People’s Republic of China Shaanxi Weinan Haren Pharmaceuticals, Ltd. People’s Republic of China |
|
| April 3, 2017 |
Biostar Pharmaceuticals NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): ?Form 10-K ?Form 20-F ?Form 11-K ?Form 10-Q ?Form N-SAR ?Form N-CSR For Period Ended: December 31, 2016 ?Transition Report on Form 10-K ?Transition Report on Form 20-F ?Transition Report on Form 11-K ?Transition Report on Form 10-Q ?Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| February 24, 2017 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2017 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. E |
|
| February 9, 2017 |
8-K 1 biostarpharma8k020717.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2017 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other |
|
| January 17, 2017 |
Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue, Xianyang, Shaanxi Province, PRC 712046 January 17, 2017 United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Ms. D. Yale Re: Request for Acceleration Biostar Pharmaceuticals, Inc. - Registration Statement on Form S-3 (File No. 333-215380) Ladies and Gentlemen: Pursuant to Rule 461 of the Securities |
|
| January 13, 2017 |
As filed with the Securities and Exchange Commission on January 13, 2017 Registration No. |
|
| December 30, 2016 |
As filed with the Securities and Exchange Commission on December 30, 2016 Registration No. |
|
| November 21, 2016 |
Biostar Pharmaceuticals 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: September 30, 2016 Or ? Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOS |
|
| November 15, 2016 |
Biostar Pharmaceuticals NT 10-Q Submission Documents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): oForm 10-K oForm 20-F oForm 11-K xForm 10-Q oForm N-SAR oForm N-CSR For Period Ended: September 30, 2016 oTransition Report on Form 10-K oTransition Report on Form 20-F oTransition Report on Form 11-K oTransition Report on Form 10-Q oTransition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| October 19, 2016 |
BSPM / Biostar Pharmaceuticals, Inc. / INTRACOASTAL CAPITAL, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biostar Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 090678301 (CUSIP Number) October 11, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| October 12, 2016 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) To Prospectus Dated December 31, 2013 Registration No. |
|
| October 12, 2016 |
Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ? Agreement?), dated as of October 11, 2016, is by and among Biostar Pharmaceuticals, Inc., a Maryland corporation (the ? Company?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a ? Buyer? and collectively, the ? Buyers?). RECITALS A. The Company and each Buyer desire to |
|
| October 12, 2016 |
Form of Warrant to purchase Shares of Common Stock. EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 BIOSTAR PHARMACEUTICALS, INC. Form of Warrant To Purchase Common Stock Warrant No.: Date of Issuance: October [•], 2016 (“Issuance Date”) Biostar Pharmaceuticals, Inc., a Maryland corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [], the registered holder hereo |
|
| October 12, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 biostarpharma8k101116.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2016 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other |
|
| October 12, 2016 |
Exhibit 99.1 Biostar Announces Execution of Agreement for $1.91 Million Registered Direct Offering of Shares of Common Stock and Warrants XIANYANG, China, October 12, 2016 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that it entered into a securities purc |
|
| September 22, 2016 |
Exhibit 99.1 Biostar Pharmaceuticals Signs a Letter of Intent to Acquire Xianyang Yongsheng Health Products Co., Ltd. XIANYANG, China, September 22, 2016 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (BSPM) (?Biostar? or ?the Company?), a PRC-based manufacturer of pharmaceutical and health supplement products, and Xianyang Yongsheng Health Products Co., Ltd., a privately held PRC-based health produ |
|
| September 22, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 biostarpharma8k092116.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2016 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Othe |
|
| August 22, 2016 |
Biostar Pharmaceuticals 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: June 30, 2016 Or ? Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR P |
|
| August 22, 2016 |
Biostar Pharmaceuticals 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: June 30, 2016 Or ? Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR P |
|
| August 16, 2016 |
Biostar Pharmaceuticals NT 10-Q biostarnt10q033116.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): oForm 10-K oForm 20-F oForm 11-K xForm 10-Q oForm N-SAR oForm N-CSR For Period Ended: June 30, 2016 oTransition Report on Form 10-K oTransition Report on Form 20-F oTransition Report on Form 11-K oTrans |
|
| August 16, 2016 |
Biostar Pharmaceuticals NT 10-Q biostarnt10q033116.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): oForm 10-K oForm 20-F oForm 11-K xForm 10-Q oForm N-SAR oForm N-CSR For Period Ended: June 30, 2016 oTransition Report on Form 10-K oTransition Report on Form 20-F oTransition Report on Form 11-K oTrans |
|
| June 13, 2016 |
Biostar Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2016 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employ |
|
| May 23, 2016 |
Biostar Pharmaceuticals 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: March 31, 2016 Or ? Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR |
|
| May 16, 2016 |
Biostar Pharmaceuticals NT 10-Q biostarnt10q033116.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): oForm 10-K oForm 20-F oForm 11-K xForm 10-Q oForm N-SAR oForm N-CSR For Period Ended: March 31, 2016 oTransition Report on Form 10-K oTransition Report on Form 20-F oTransition Report on Form 11-K oTran |
|
| April 22, 2016 |
Biostar Pharmaceuticals DEF 14A biostarpharma-def14a041516.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 14, 2016 |
Biostar Pharmaceuticals 10-K (Annual Report) 10-K 1 biostarpharma10k123115.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2015 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| April 14, 2016 |
Biostar Pharmaceuticals, Inc. List of subsidiaries EX-21 2 ex21.htm EX-21 Exhibit 21 Biostar Pharmaceuticals, Inc. List of subsidiaries As of December 31, 2015 Name Place of incorporation Shaanxi Biostar Biotech Ltd People’s Republic of China Shaanxi Aoxing Pharmaceutical Co. Ltd. People’s Republic of China Shaanxi Weinan Haren Pharmaceuticals, Ltd. People’s Republic of China |
|
| March 31, 2016 |
Biostar Pharmaceuticals NT 10-K biostarpharma-nt10k123115.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 301 (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: December 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report |
|
| February 24, 2016 |
Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price ex99-1.htm Exhibit 99.1 Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price XIANYANG, China, February 24, 2016 - Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (?Biostar?), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 22, 2016, NASDAQ notified the Company that it had regained co |
|
| February 24, 2016 |
Financial Statements and Exhibits, Other Events biostar8k022316.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2016 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction ( |
|
| February 5, 2016 |
Biostar Pharmaceuticals to Effect Reverse Stock Split EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Biostar Pharmaceuticals to Effect Reverse Stock Split XIANYANG, China, February 5, 2016 - Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar” or “the Company”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that its Board of Directors unanimously approved a reverse split of i |
|
| February 5, 2016 |
biostar8k020416.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2016 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (C |
|
| February 5, 2016 |
Articles of Amendment to the Articles of Incorporation. ex3-1.htm Exhibit 3.1 ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF BIOSTAR PHARMACEUTICALS, INC. Biostar Pharmaceuticals, Inc. a Maryland corporation (the ?Corporation?), hereby certifies to the State Department of Assessments and Taxation of Maryland that: This is to certify that: FIRST: Article SIXTH of the Articles of Incorporation of Biostar Pharmaceuticals, Inc. a Maryland corpor |
|
| November 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: September 30, 2015 Or ? Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOS |
|
| November 17, 2015 |
Biostar Pharmaceuticals NT 10-Q biostar-nt10q093015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 202 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: September 30, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on F |
|
| October 26, 2015 |
Biostar Pharmaceuticals DEF 14A biostar-def14a102315.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| August 28, 2015 |
Biostar Pharmaceuticals 8-K (Current Report/Significant Event) biostar8k082715.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2015 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Co |
|
| August 19, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: June 30, 2015 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR P |
|
| August 17, 2015 |
Biostar Pharmaceuticals NT 10-Q biostarpharma-nt10q063015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 202 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: June 30, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on |
|
| May 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: March 31, 2015 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR |
|
| April 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2014 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR PHARM |
|
| April 15, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition biostarpharma8k041515.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2015 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdictio |
|
| April 15, 2015 |
EX-21 2 ex21.htm EX-21 Exhibit 21 Biostar Pharmaceuticals, Inc. List of subsidiaries As of December 31, 2014 Name Place of incorporation Shaanxi Biostar Biotech Ltd People’s Republic of China Shaanxi Aoxing Pharmaceutical Co. Ltd. People’s Republic of China Shaanxi Weinan Haren Pharmaceuticals, Ltd. People’s Republic of China |
|
| April 15, 2015 |
Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results ex99-1.htm Exhibit 99.1 Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results Full Year 2014 Financial Highlights ? Net sales increased by $8.7 million, or 16.5%, year over year, from $52.7 million in 2013 to $61.4 million in 2014. ? Gross profit grew by approximately 17.9% from $25.7 million in 2013 to $30.3 million in 2014. ? Cash and cash equivalents wa |
|
| April 1, 2015 |
Biostar Pharmaceuticals NT 10-K biostarpharma-nt10k123114.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 202 (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: December 31, 2014 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report |
|
| December 5, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2014 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Em |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: September 30, 2014 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOS |
|
| October 24, 2014 |
BSPM / Biostar Pharmaceuticals, Inc. DEF 14A - - DEF 14A DEF 14A 1 biostarpharma-def14a100714.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permit |
|
| October 23, 2014 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2014 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Em |
|
| October 23, 2014 |
Clement Letter dated October 23, 2014. Exhibit 16.1 October 23, 2014 Office of the Chief Accountant Securities and Exchange Commission 460 Fifth Street N. W. Washington, DC 20549 Re : Biostar Pharmaceuticals, Inc. Commission File Number: 001-34708 Dear Sirs, We have received a copy of, and are in agreement with, the statements pertaining to our firm being made by Biostar Pharmaceuticals, Inc. in Item 4.01 of its Form 8-K dated October |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: June 30, 2014 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR P |
|
| July 17, 2014 |
Exhibit 4.1 BIOSTAR PHARMACEUTICALS, INC. 2013 EQUITY INCENTIVE PLAN, INC. Section 1. Purpose. The purpose of the Biostar Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the “Plan”) is to attract and retain outstanding individuals as Key Employees, Directors and Consultants of the Company and its Subsidiaries, to recognize the contributions made to the Company and its Subsidiaries by Key Employe |
|
| July 17, 2014 |
BSPM / Biostar Pharmaceuticals, Inc. S-8 - - S-8 Registration No. 333- As filed with the Securities and Exchange Commission on July 17, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I. |
|
| May 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: March 31, 2014 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR |
|
| March 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2013 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR PHARM |
|
| March 10, 2014 |
424B5 1 biostarpharma424b5-0308014.htm 424B5 Prospectus Supplement Filed pursuant to Rule 424(b)(5) To Prospectus Dated December 31, 2013 Registration No. 333-192963 Biostar Pharmaceuticals, Inc. 1,650,000 shares of common stock Warrants to purchase 660,000 shares of common stock 660,000 shares of common stock issuable upon exercise of the warrants Pursuant to this prospectus supplement and the ac |
|
| March 10, 2014 |
Securities Purchase Agreement, dated March 10, 2014, by and between the Company and the Investors. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 10, 2014, is by and among Biostar Pharmaceuticals, Inc., a Maryland corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company and each Buyer desire to enter |
|
| March 10, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Empl |
|
| March 10, 2014 |
Form of Warrant to purchase Shares of Common Stock by the Company in favor of the Investors. EX-4.1 3 ex4-1.htm EX-4.1 Exhibit 4.1 [FORM OF WARRANT] BIOSTAR PHARMACEUTICALS, INC. Warrant To Purchase Common Stock Warrant No.: Date of Issuance: March [], 2014 (“Issuance Date”) Biostar Pharmaceuticals, Inc., a Maryland corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [], the registered holde |
|
| March 10, 2014 |
EX-1.1 2 ex1-1.htm EX-1.1 Exhibit 1.1 CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: This letter (the “Agreement”) confirms Moody Capital Solutions, Inc. (“Moody Capital”) engagement as |
|
| March 10, 2014 |
Exhibit 99.1 Biostar Announces Execution of Agreement for $4.1 Million Registered Direct Offering of Shares of Common Stock and Warrants XIANYANG, China, March 10, 2014 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today |
|
| February 20, 2014 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With Last Year’s USD$21.8 million loss from operations XIANYANG, China, February 20, 2014 –Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for |
|
| February 20, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2014 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. E |
|
| December 31, 2013 |
As filed with the Securities and Exchange Commission on December 31, 2013 Registration No. |
|
| December 19, 2013 |
Form of Unsubordinated Indenture* Exhibit 4.1 BIOSTAR PHARMACEUTICALS, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 DEFINITIONS 1 SECTION 1.2 COMPLIANCE CERTIFICATES AND OPINIONS 8 SECTION 1.3 FORM OF DOCUMENTS DELIVERED TO TRUSTEE 8 SECTION 1.4 ACTS OF HOLDERS; RECORD DATES 9 SECTION 1.5 NOTICES, ETC., TO |
|
| December 19, 2013 |
Form of Subordinated Indenture* Exhibit 4.2 BIOSTAR PHARMACEUTICALS, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1 DEFINITIONS 1 SECTION 1.2 COMPLIANCE CERTIFICATES AND OPINIONS 9 SECTION 1.3 FORM OF DOCUMENTS DELIVERED TO TRUSTEE 10 SECTION 1.4 ACTS OF HOLDERS; RECORD DATES 10 SECTION 1.5 NOTICES, |
|
| December 19, 2013 |
As filed with the Securities and Exchange Commission on December 19, 2013 Registration No. |
|
| November 27, 2013 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2013 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. E |
|
| November 14, 2013 |
Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule Exhibit 99.1 Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule XIANYANG, China, Nov. 13, 2013 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on November 11, 2013, NASDAQ notified the |
|
| November 14, 2013 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2013 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. E |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: September 30, 2013 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOS |
|
| November 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2013 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Em |
|
| October 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| August 28, 2013 |
2012 Stock Option Compensation Plan* Exhibit 4.1 Biostar Pharmaceuticals, Inc. 2012 Stock Option Compensation Plan This Biostar Pharmaceuticals, Inc. 2012 Stock Option Compensation Plan (the "Plan") is designed to retain directors, executives and selected employees and consultants and reward them for making major contributions to the success of the Company. These objectives are accomplished by making long-term incentive awards under |
|
| August 28, 2013 |
Registration No. 333- As filed with the Securities and Exchange Commission on August 28, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 ( |
|
| August 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: June 30, 2013 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR P |
|
| August 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 202 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: June 30, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| May 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: March 31, 2013 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR |
|
| May 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2013 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employe |
|
| April 16, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2013 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Empl |
|
| April 16, 2013 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. Reports 2012 Results XIANYANG, China, April 15, 2013 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced financial results for the full year ended December 31, 20 |
|
| April 15, 2013 |
EX-10.7 2 ex10-7.htm Exhibit 10.7 Product Research and Development Agreement Party A: Shaanxi Aoxing Pharmaceutical Co. Ltd. Party B: Life Science Academy of Northwest University Party A and Party B reached the following R&D agreement regarding National Type I new medicine Danshensu Borneol Ester through friendly negotiation: 1. Project Name: R&D of National Type I new medicine Danshensu Borneol E |
|
| April 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2012 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR PHARM |
|
| April 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: December 31, 2012 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR |
|
| March 15, 2013 |
Exhibit 10.1 [Unofficial Translation] SUPPLEMENTAL AGREEMENT TO SHARE TRANSFER CONTRACT OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. BY AND BETWEEN SHAANXI AOXING PHARMACEUTICALS CO., LTD. AND FORMER SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. Supplemental Agreement Party A: Shaanxi Aoxing Pharmaceuticals Co., Ltd. (hereinafter referred to as “Transferee”) Party B: All Fo |
|
| March 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2013 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Empl |
|
| January 11, 2013 |
Mazars CPA Limited Letter dated January 9, 2013. Exhibit 16.1 Our ref.: PS/BL/B397/ABA2 January 9, 2013 Securities and Exchange Commission 100 F Street, NE Washington DC 20549 United States Dear Sirs, BIOSTAR PHARMACEUTICALS, INC. We have read Item 4.01(a) of Biostar Pharmaceuticals, Inc’s Form 8-K, which discusses the resignation of Mazars CPA Limited as its independent registered public accounting firm, and we agree with the statements made th |
|
| January 11, 2013 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2013 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Emp |
|
| December 20, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2012 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. E |
|
| November 19, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: September 30, 2012 Or ? Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOS |
|
| November 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-34708 CUSIP NUMBER: 090678 202 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: September 30, 2012 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| October 26, 2012 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2012 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Em |
|
| September 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| August 17, 2012 |
2011 Stock Option Compensation Plan * Exhibit 4.1 Biostar Pharmaceuticals, Inc. 2011 Stock Option Compensation Plan This Biostar Pharmaceuticals, Inc. 2011 Stock Option Compensation Plan (the "Plan") is designed to retain directors, executives and selected employees and consultants and reward them for making major contributions to the success of the Company. These objectives are accomplished by making long-term incentive awards under |
|
| August 17, 2012 |
Registration No. 333- As filed with the Securities and Exchange Commission on August 17, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 ( |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: June 30, 2012 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR P |
|
| August 6, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2012 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Empl |
|
| August 6, 2012 |
Exhibit 99.1 FOR IMMEDIATE RELEASE BIOSTAR PHARMACEUTICALS, INC. RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTART SALES OF ITS GEL CAPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today |
|
| May 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: March 31, 2012 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR |
|
| April 24, 2012 |
Amendment No. 1 to the Employment Agreement. Exhibit 10.1 Amendment No. 1 to the Employment Agreement This Amendment No. 1 (the “Amendment”) to Employment Agreement is made as of this 20th day of April, 2012, by and between Biostar Pharmaceuticals, Inc., a Maryland corporation, with offices at No. 588 Shiji Xi Avenue, Xianyang, Shaanxi Province, PRC (the “Company”) and Zack Zibing Pan, the Company’s Chief Financial Officer residing in Oklaho |
|
| April 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2012 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Empl |
|
| April 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2012 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Emplo |
|
| April 4, 2012 |
Articles of Amendment to the Articles of Incorporation Exhibit 3.1 ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF BIOSTAR PHARMACEUTICALS, INC. Biostar Pharmaceuticals, Inc. a Maryland corporation (the “Corporation”), hereby certifies to the State Department of Assessments and Taxation of Maryland that: This is to certify that: FIRST: Article SIXTH of the Articles of Incorporation of Biostar Pharmaceuticals, Inc. a Maryland corporation (the |
|
| April 4, 2012 |
BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCK SPLIT Exhibit 99.1 FOR IMMEDIATE RELEASE BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCK SPLIT XIANYANG, China, April 3, 2012 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or “the Company”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its Board of Directors unanimo |
|
| March 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended: December 31, 2011 Or ? Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR PHARM |
|
| March 27, 2012 |
Exhibit 21 List of subsidiary / variable interest entities of Biostar Pharmaceuticals, Inc. as of December 31, 2011 Subsidiary Place of incorporation Shaanxi Biostar BioTech Ltd. People?s Republic of China Variable interest entities Place of incorporation Shaanxi Aoxing Pharmaceutical Co., Ltd, People?s Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, LLC People?s Republic of China |
|
| December 23, 2011 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On October 11, 2011, Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or the “Company”), through its wholly owned variable interest entity, Shaanxi Aoxing Pharmaceutical Co., Ltd., acquired 100% equity interest (the “Acquisition”) of Shaanxi Weinan Aoxing Pharmaceutical, LLC (formerly Shaanxi Weinan Huaren Pharmaceu |
|
| December 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2011 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (C |
|
| December 23, 2011 |
Exhibit 99.1 Shaanxi Weinan Aoxing Pharmaceuticals, LLC (formerly Shaanxi Weinan Huaren Pharmaceuticals, Ltd.) Index to Financial Statements Year ended December 31, 2010 Page Report of Independent Registered Public Accounting Firm F-1 Balance Sheet F-2 Statement of Operations F-3 Statement of Stockholders’ Equity F-4 Statement of Cash Flows F-5 Notes to Financial Statements F-6 to F-16 Report of I |
|
| November 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: September 30, 2011 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOS |
|
| October 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2011 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Em |
|
| October 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2011 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Em |
|
| October 25, 2011 |
BIOSTAR PHARMACEUTICALS ACQUIRES SHAANXI WEINAN HUAREN PHARMACEUTICALS, LTD. Exhibit 99.1 FOR IMMEDIATE RELEASE BIOSTAR PHARMACEUTICALS ACQUIRES SHAANXI WEINAN HUAREN PHARMACEUTICALS, LTD. XIANYANG, China, October 25, 2011 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a developer, manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions, today announced that on October 20, 2011, it |
|
| October 11, 2011 |
Exhibit 10.1 SHARE TRANSFER CONTRACT OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. BY AND BETWEEN SHAANXI AOXING PHARMACEUTICALS CO., LTD. AND SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD. INDEX CHAPATER I DEFINITION AND INTERPRETATION 4 ARTICLE 1 DEFINITION 4 CHAPATER II TRANSFERRED SHARES 5 ARTICLE 2 SHARE TRANSFER 5 ARTICLE 3 TRANSFER PRICE 5 ARTICLE 4 CONDITIONS FOR THE |
|
| October 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2011 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Em |
|
| October 11, 2011 |
BIOSTAR PHARMACEUTICALS SIGNS AGREEMENT TO ACQUIRE SHAANXI WEINAN HUAREN PHARMACEUTICALS, LTD. Exhibit 99.1 FOR IMMEDIATE RELEASE BIOSTAR PHARMACEUTICALS SIGNS AGREEMENT TO ACQUIRE SHAANXI WEINAN HUAREN PHARMACEUTICALS, LTD. XIANYANG, China, October 11, 2011 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a developer, manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions, today announced that its w |
|
| October 11, 2011 |
Form Non-competition Agreement Exhibit 10.2 Form Non-competition Agreement This Non-competition Agreement (this “Agreement”) is entered into by and between the following parties in [] on [], 2011. Party A: Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd., a company incorporated under PRC law, with its business license registered number [] and its legal address registered at No. 13, Weihua Road, Weinan City, Shaanxi Province; Par |
|
| September 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| August 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: June 30, 2011 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR P |
|
| July 18, 2011 |
Slide presentation (furnished pursuant to Item 7.01 hereof). Exhibit 99.1 |
|
| July 18, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2011 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Emplo |
|
| May 25, 2011 |
Chairman and CEO of Biostar Pharmaceuticals, Inc. Adopts 10b5-1 Share Repurchase Plan Exhibit 99.1 Chairman and CEO of Biostar Pharmaceuticals, Inc. Adopts 10b5-1 Share Repurchase Plan On May 25, 2011 ? Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules (?Xin Aoxing Capsules?), and a variety of pharmaceutical products, today announced that, following the Board?s approval |
|
| May 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2011 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employ |
|
| May 19, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A Amendment No. 1 (Mark One) x Annual Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended: December 31, 2010 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001- |
|
| May 16, 2011 |
Employment Agreement with Zack Zibing Pan dated April 7, 2011* Exhibit 10.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement") is made as of this seventh day of April, 2011, by and between Biostar Pharmaceuticals, Inc., a Maryland corporation, having an office at No. 588 Shiji Xi Avenue, Xianyang, Shaanxi Province, People’s Republic of China (hereinafter referred to as the "Company") and Zack Pan an individual residing at Oklahoma City, Oklahoma |
|
| May 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2011 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employ |
|
| May 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: March 31, 2011 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR |
|
| May 16, 2011 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. Reports First Quarter 2011 Results; Revenues Increase 24% to $15.3 Million with Adjusted EPS of $0.11 XIANYANG, China, May 16, 2011 - Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing Capsules"), and |
|
| April 12, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2011 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Emplo |
|
| April 12, 2011 |
Exhibit 99.1 BioStar Pharmaceuticals Inc. Announces Appointment of New Chief Financial Officer; Appoints Audit Committee Chairman and Independent Director to the Board of Directors XIANYANG, China, April 12, 2011 – Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or “the Company”), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid C |
|
| March 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended: December 31, 2010 Or ? Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR PHARM |
|
| February 25, 2011 |
February 25, 2011 Ms. Keira Nakada Staff Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Biostar Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide the Company’s responses to the February 16, 2011 commen |
|
| February 18, 2011 |
Biostar Pharmaceuticals to Host Virtual Presentation February 18th at 10:30 AM EST EX-99.2 3 ex99-2.htm Exhibit 99.2 Biostar Pharmaceuticals to Host Virtual Presentation February 18th at 10:30 AM EST XIANYANG, China, Feb. 17, 2011 - Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), Xianyang, PRC-based manufacturer of an over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of other pharmaceutical products in the PRC, to |
|
| February 18, 2011 |
Slide presentation (furnished pursuant to Item 7.01 hereof). Exhibit 99.1 |
|
| February 18, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2011 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. E |
|
| January 13, 2011 |
January 13, 2011 Keira Nakada Staff Accountant Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Biostar Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2009 Filed March 31, 2010 File No. 001-34708 Dear Keira Nakada: The purpose of this letter is to provide the Company’s responses to the December 29, 2010 comment let |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or organ |
|
| November 15, 2010 |
BIOSTAR PHARMACEUTICALS, INC. REPORTS THIRD QUARTER REVENUE INCREASE OF 29.7% TO $20.2 MILLION Exhibit 99.1 BIOSTAR PHARMACEUTICALS, INC. REPORTS THIRD QUARTER REVENUE INCREASE OF 29.7% TO $20.2 MILLION XIANYANG, China, November 15, 2010 (Xinhua-PRNewswire-FirstCall) ? Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (?Biostar? or ?the Company?), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules (?Xin Aoxing Capsules?), and a v |
|
| November 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: September 30, 2010 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOS |
|
| October 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 27, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or organi |
|
| October 25, 2010 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500 XIANYANG, China, Oct 25/PRNewswire-Asia-FirstCall/ - Biostar Pharmaceuticals, Inc. (Nasdaq:BSPM - News) ("Biostar" or "the Company"), a Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin A |
|
| October 25, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 25, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or organi |
|
| October 1, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 DEFINITIVE SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x |
|
| September 13, 2010 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or orga |
|
| September 13, 2010 |
Executive Summary of Biostar Pharmaceuticals, Inc. Exhibit 99.2 |
|
| September 13, 2010 |
Presentation of Biostar Pharmaceuticals, Inc. Exhibit 99.1 |
|
| September 7, 2010 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 12:30 pm ET XIANYANG, China, Sep. 7 - Biostar Pharmaceuticals, Inc. (Nasdaq:BSPM) ("Biostar" or "the Company"), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing Capsules"), and a variety o |
|
| September 7, 2010 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or organ |
|
| August 17, 2010 |
BIOSTAR PHARMACEUTICALS, INC. SECOND QUARTER REVENUE INCREASED 46.4% TO $19.4 MILLION Exhibit 99.1 BIOSTAR PHARMACEUTICALS, INC. SECOND QUARTER REVENUE INCREASED 46.4% TO $19.4 MILLION XIANYANG, China, August 17, 2010 – Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or “the Company”), a Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules (“Xin Aoxing Capsules”), and a variety of pharmaceutical products, toda |
|
| August 17, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 17, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or organiz |
|
| August 13, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: June 30, 2010 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR P |
|
| August 13, 2010 |
Exhibit 10.2 (English Translation) LABOR CONTRACT Party A: Shaanxi Aoxing Pharmaceutical Co., Ltd. Address: Chenyangzhai, Xianyang Legal Representative: Ronghua Wang Party B: Ronghua Wang Address: Shenjia Xiaoqu, Floor 21, Room 3103, Qindu District, Xiayang ID number: xxxxxxxxxxxxxxx Party A and Party B (the ?Parties?) hereby enter into the following agreement pursuant to the Labor Contract Law of |
|
| July 6, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or organizati |
|
| July 6, 2010 |
BIOSTAR PHARMACEUTICALS, INC. APPOINTS NEW CHIEF FINANCIAL OFFICER Exhibit 99.1 BIOSTAR PHARMACEUTICALS, INC. APPOINTS NEW CHIEF FINANCIAL OFFICER XIANYANG, China, July 6, 2010 (Xinhua-PRNewswire-FirstCall) – Biostar Pharmaceuticals, Inc. (BSPM.Nasdaq) ("Biostar" or "the Company"), the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin-Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, today announced that Mr. Deyin |
|
| July 2, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or organizati |
|
| July 2, 2010 |
Exhibit 99.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement") is made as of this 30th day of June, 2010, by and between Biostar Pharmaceuticals, Inc., a Maryland corporation, having an office at No. 588 Shiji Xi Avenue, Xianyang, Shaanxi Province, People’s Republic of China (hereinafter referred to as the "Company") and Deyin Chen (陈德胤), an individual residing at 300 Jinxiu Road, S |
|
| May 25, 2010 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line Increases overall capacity by $30 million annually and paves way for entrance into the Military Pharmaceutical Market XIANYANG, China, May 25, 2010 (Xinhua-PRNewswire-FirstCall) - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM - News) ("Biostar" or "the Company"), the Xianyang-based manufacturer of a leading over-the |
|
| May 25, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or organizati |
|
| May 17, 2010 |
BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS Exhibit 99.1 BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS XIANYANG, China, May 17, 2010 (Xinhua-PRNewswire-FirstCall) ? Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (?Biostar? or ?the Company?), a Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules (?Xin Aoxing?), and a variety of pharmaceutical produ |
|
| May 17, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 001-34708 20-8747899 (State or other jurisdiction of incorporation or organizati |
|
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the quarterly period ended: March 31, 2010 Or ¨ Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to Commission File Number: 001-34708 BIOSTAR |
|
| May 14, 2010 |
Exhibit 10.28 (English Translation) ASSETS ACQUISITION AGREEMENT Party A: Shaanxi Biostar Biotech, Ltd. Legal Representative: WANG Ronghua Party B: Xi?an Meipude Bio-Technology Co., Ltd. Legal Representative: SUN Yaomei On March 28, 2010, Party A and Party B again entered into the following agreement concerning Party A?s acquisition of Party B?s assets. A. Party B agrees to transfer all of the tec |
|
| May 12, 2010 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010 First Quarter Earnings Conference Call on Monday, May 17, 2010 at 9:30 a.m. ET XIANYANG, China, May 12, 2010 (Xinhua-PRNewswire-FirstCall) – Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or “the Company”), a Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsu |
|
| May 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-8747899 (State or other jurisdiction of incorporation or organizat |
|
| April 28, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-5101287 (State or other jurisdiction of incorporation or organiz |
|
| April 28, 2010 |
Exhibit 99.1 BIOSTAR PHARMACEUTICALS, INC. RECEIVES NEW ADVERTISING APPROVAL FROM SHAANXI SFDA FOR MARKETING XIN AOXING CAPSULE XIANYANG, China, April 27, 2010 (Xinhua-PRNewswire-FirstCall) – Biostar Pharmaceuticals, Inc. (NASDAQ Global Market: BSPM) ("Biostar" or "the Company"), the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule ( |
|
| April 21, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant in its charter) Maryland 20-8747899 (State of incorporation or organization) ( I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xia |
|
| March 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-147363 BIOSTAR PHARMACEUTICALS, |
|
| March 31, 2010 |
Wu Quan Mountain Land Use Transfer Agreement * Exhibit 10.27 (English Translation) Wu Quan Mountain Land Use Transfer Agreement Party A: Village Committee of the Wu Quan Village, Jiang Cun Town, Hu County (Transferor) Party B: Shaanxi Aoxing Pharmaceutical Co., Ltd. (Transferee) In order to fully develop and use the mountain land and improve land utilization and economic benefits, the parties enter into the following agreement pursuant to the |
|
| March 9, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-5101287 (State or other jurisdiction of incorporation or organiza |
|
| March 9, 2010 |
Presentation of Biostar Pharmaceuticals, Inc. Exhibit 99.1 |
|
| March 9, 2010 |
Executive Summary of Biostar Pharmaceuticals, Inc. Exhibit 99.2 |
|
| March 1, 2010 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) – Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) (“Biostar” or “the Company”), the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsu |
|
| March 1, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-5101287 (State or other jurisdiction of incorporation or organiza |
|
| February 25, 2010 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Biostar Pharmaceuticals, Inc. Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operating Income of $16 – $17 million excluding non-cash charges XIANYANG, China, February 25, 2010 (Xinhua-PRNewswire-FirstCall) – Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM – News) (“Biostar” or “the Company”), a Xianyang-based developer, manufacturer a |
|
| February 25, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-5101287 (State or other jurisdiction of incorporation or orga |
|
| January 28, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-8747899 (State or other jurisdiction of in |
|
| January 28, 2010 |
Letter from Morgenstern, Svoboda & Baer CPA’s P.C. dated January 28, 2010. Exhibit 16.1 Morgenstern, Svoboda & Baer CPA?s P.C. January 28, 2010 Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Biostar Pharmaceuticals, Inc. Commission File No. 333-147363 Dear Sir or Madame: We have read the disclosure of Biostar Pharmaceuticals, Inc. (the ?Company?) set forth in Item 4.01, ?Changes in Registrant?s Certifying Accountant", of the Company's C |
|
| January 28, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2010 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-8747899 (State or other jurisdiction of incorporation or organ |
|
| January 28, 2010 |
Letter from Acquavella, Chiarelli, Shuster, Berkower & Co., LLP dated January 28, 2010 (1) Exhibit 16.1 Acquavella, Chiarelli, Shuster, Berkower & Co., LLP January 28, 2010 Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Biostar Pharmaceuticals, Inc. Commission File No. 333-147363 Dear Sir or Madame: We have read the disclosure of Biostar Pharmaceuticals, Inc. (the ?Company?) set forth in Item 4.01, ?Changes in Registrant?s Certifying Accountant", of th |
|
| January 28, 2010 |
Biostar Pharmaceuticals, Inc. Announces Change of Auditor Exhibit 99.1 Biostar Pharmaceuticals, Inc. Announces Change of Auditor XIANYANG, China, January 28, 2010 (Xinhua-PRNewswire-FirstCall) – Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM – News) (“Biostar” or “the Company”), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced t |
|
| January 5, 2010 |
Exhibit 99.2 Biostar Pharmaceuticals Strengthens Corporate Governance with Appointments of New Independent Directors, Establishment of Board Committees and Adoption of Code of Ethics Xi?an, China ? January 4, 2010 ? Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM ? News) (?Biostar? or ?the Company?), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medic |
|
| January 5, 2010 |
Code of Business Conduct and Ethics Exhibit 14.1 BIOSTAR PHARMACEUTICALS, INC. CODE OF ETHICS Dated: December 30, 2009 POLICY STATEMENT Ethical business conduct is critical to our business and the responsibility of all of us. It is the policy of Biostar Pharmaceuticals, Inc. to conduct its affairs in accordance with all applicable laws and regulations. The Code of Business Conduct and Ethics (the ?Code?) applies to the employees, of |
|
| January 5, 2010 |
Exhibit 99.1 BIOSTAR PHARMACEUTICALS, INC. To: [Director Name] [Address] Dear [Director Name]: This is to confirm the terms of your appointment as a Non-Executive Director and as [] of Biostar Pharmaceuticals, Inc. (the ?Company?). Overall, in terms of time commitment, we expect your attendance at all the Board of Directors (the "Board") meetings, meetings of the audit, compensation and nomination |
|
| January 5, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-5101287 (State or other jurisdiction of incorporation or orga |
|
| December 30, 2009 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai Management anticipates $9 million in 2010 revenues from this initiative XIANYANG, China, December 29, 2009 (Xinhua-PRNewswire-FirstCall) ? Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM ? News) (?Biostar? or ?the Company?), a Xianyang-based developer, manufacturer and supplier o |
|
| December 30, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-5101287 (State or other jurisdiction of incorporation or orga |
|
| December 16, 2009 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Maryland 333-147363 20-5101287 (State or other jurisdiction of incorporation or orga |
|
| December 16, 2009 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. Secures Letter of Intent to Acquire Xi’an-Based Medical Equipment and Nutrients Manufacturer Potential acquisition will expand product portfolio and Introduces Medical Devices to BioStar’s Distribution Network XIANYANG, China, December 16, 2009 (Xinhua-PRNewswire-FirstCall) – Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM – News) (“Biostar” or “t |
|
| November 19, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 333-147363 20-5101287 (State or other jurisdiction of incorporation) (C |
|
| November 19, 2009 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 18, 2009, by and among Biostar Pharmaceuticals, Inc., a Maryland corporation, with headquarters located at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People’s Republic of China 712046 (the “Company”), and the Buyers listed on the Schedule of Buyers attached hereto (indi |
|
| November 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 333-147363 20-5101287 (State or other jurisdiction of incorporation) (C |
|
| November 13, 2009 |
Exhibit 99.1 Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results - Q3 2009 revenue increased 106.3% to $15.6 million; Q3 Gross Margins of 77.0% - Q3 2009 net income increased 459.2% to $3.1 million with EPS of $0.13 - Revenue for the first nine months increased 52.5 % to $36.2 million; net income increased 112.9% to $8.8 million with EPS of $0.37 - Cash flow from op |
|
| November 12, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20-549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20-549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 333-147363 BIOSTAR PHARMACEUTICALS, INC. (Exact name |
|
| November 9, 2009 |
EX-99.3 4 ex99-3.htm EXHIBIT 99.3 BIOSTAR PHARMACEUTICALS, INC. TO HOST FISCAL YEAR 2009 THIRD QUARTER EARNINGS CONFERENCE CALL ON THURSDAY, NOVEMBER 12, 2009 AT 9:30 A.M. ET Press Release Source: Biostar Pharmaceuticals, Inc. On 8:00 am EST, Monday November 9, 2009 XIANYANG, China, Nov. 9 /PRNewswire-Asia-FirstCall/ - Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM - News; "Biostar" or "t |
|
| November 9, 2009 |
BIOSTAR PHARMACEUTICALS, INC. TO PRESENT AT THE BREAN MURRAY, CARRET & CO. CHINA GROWTH CONFERENCE EX-99.1 2 ex99-1.htm Exhibit 99.1 BIOSTAR PHARMACEUTICALS, INC. TO PRESENT AT THE BREAN MURRAY, CARRET & CO. CHINA GROWTH CONFERENCE Press Release Source: Biostar Pharmaceuticals, Inc. On 8:00 am EST, Wednesday November 4, 2009 XIANYANG, China, Nov. 4 /PRNewswire-Asia-FirstCall/ - Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM - News; "Biostar" or "the Company"), a Xianyang-based develope |
|
| November 9, 2009 |
BIOSTAR PHARMACEUTICALS ANNOUNCES CLOSING OF A $3.6 MILLION EQUITY FINANCING EXHIBIT 99.2 BIOSTAR PHARMACEUTICALS ANNOUNCES CLOSING OF A $3.6 MILLION EQUITY FINANCING Press Release Source: Biostar Pharmaceuticals, Inc. On 8:00 am EST, Friday November 6, 2009 XIANYANG, China, Nov. 6 /PRNewswire-Asia-FirstCall/ - Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM - News; "Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical |
|
| November 9, 2009 |
Other Events, Financial Statements and Exhibits 8-K 1 biostar-8k110909.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation |
|
| November 3, 2009 |
Exhibit 3.1 ARTICLES SUPPLEMENTARY TO THE ARTICLES OF INCORPOATION OF BIOSTAR PHARMACEUTICALS, INC. Biostar Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Maryland (the “Corporation”), hereby certifies to the State Department of Assessments and Taxation of Maryland, that: FIRST: Pursuant to the authority granted to and vested in the Board of Directors of |
|
| November 3, 2009 |
Exhibit 99.2 MAKE GOOD ESCROW AGREEMENT This Agreement, dated as of November 2, 2009 (this “Agreement”), is entered into by and among Biostar Pharmaceuticals, Inc., a Maryland corporation (the “Company”), Barron Partners LP, Fernando Oscar Liu, Olga Filippova, Andrew Barron Worden, Steven Mazur, Golden1177 LP, RossPlan LP, JBWA2 LP, LeeMadison9189 LP, XWRT2 LP, Godfrey2468 LP, SBMT2 LP, Tibero2 LP |
|
| November 3, 2009 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 2, 2009, by and among Biostar Pharmaceuticals, Inc., a Maryland corporation, with headquarters located at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People’s Republic of China 712046 (the “Company”), and the Buyers listed on the Schedule of Buyers attached hereto (indiv |
|
| November 3, 2009 |
Exhibit 99.3 CLOSING ESCROW AGREEMENT This Agreement, dated as of November 2, 2009 (this “Agreement”), is entered into by and among Biostar Pharmaceuticals, Inc., a Maryland corporation (the “Company”), Barron Partners LP, Fernando Oscar Liu, Olga Filippova, Andrew Barron Worden, Steven Mazur, Golden1177 LP, RossPlan LP, JBWA2 LP, LeeMadison9189 LP, XWRT2 LP, Godfrey2468 LP, SBMT2 LP, Tibero2 LP, |
|
| November 3, 2009 |
Exhibit 4.1 NEITHER THE SECURITIES REPRESENTED BY THIS WARRANT NOR THE UNDERLYING SHARES OF COMMON STOCK HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR ANY STATE SECURITIES LAWS AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFE |
|
| November 3, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation) 333-147363 (Commission Fi |
|
| October 6, 2009 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation) 333-147363 (Commission Fil |
|
| October 6, 2009 |
BIOSTAR PHARMACEUTICALS, INC. RECEIVES PATENT FOR AOXING GANBAO Exhibit 99.1 BIOSTAR PHARMACEUTICALS, INC. RECEIVES PATENT FOR AOXING GANBAO Press Release Source: Biostar Pharmaceuticals, Inc. On Friday October 2, 2009, 8:00 am EDT XIANYANG, China, Oct. 2 /PRNewswire-Asia-FirstCall/ - Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM - News; "Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and |
|
| August 28, 2009 |
Biostar Pharmaceuticals, Inc. 2009 Incentive Stock Option Plan. Exhibit 4.1 BIOSTAR PHARMACEUTICALS, INC. 2009 INCENTIVE STOCK PLAN This Biostar Pharmaceuticals, Inc. 2009 Incentive Stock Plan (the "Plan") is designed to retain directors, executives and selected employees and consultants and reward them for making major contributions to the success of the Company. These objectives are accomplished by making long-term incentive awards under the Plan thereby pro |
|
| August 28, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland 20-5101287 (State of other jurisdiction of incorporation or organization (I.R.S. Employer Identification No.) No. 588 Shiji Xi Road, Xianyang, Shaanxi Province, The Peop |
|
| August 18, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation) 333-147363 (Commission Fil |
|
| August 18, 2009 |
Exhibit 99.1 BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2009 FINANCIAL RESULTS Second Quarter 2009 Revenue Increased 40.6% to Approximately $13.2 Million and Net Income Increased 119.3% to Approximately $3.9 Million with EPS of $0.17 Gross Margins Improved 1630-Basis Points to 73.5% over Q2 2008 Press Release Source: Biostar Pharmaceuticals, Inc. On Friday August 14, 2009, 7:30 am EDT |
|
| August 18, 2009 |
Exhibit 99.2 BIOSTAR PHARMACEUTICALS, INC. TO HOST FISCAL YEAR 2009 SECOND QUARTER EARNINGS CONFERENCE CALL ON FRIDAY, AUGUST 14, 2009 AT 10:30 A.M. EDT Press Release Source: Biostar Pharmaceuticals, Inc. On Wednesday August 12, 2009, 7:30 am EDT XIANYANG, China, Aug. 12 /PRNewswire-Asia-FirstCall/ - Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM - News; "Biostar" or "the Company"), a Xia |
|
| August 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20-549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20-549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 333-147363 BIOSTAR PHARMACEUTICALS, INC. (Exact |
|
| August 13, 2009 |
Exhibit 10.1 |
|
| August 6, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation) 333-147363 (Commission File |
|
| August 6, 2009 |
Exhibit 10.1 |
|
| July 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2009 BIOSTAR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation) 333-147363 (Commission File |
